Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Nina D. Wagner-Johnston"'
Autor:
Nancy L. Bartlett, Felicia Gomez, Matthew Mosior, Malachi Griffith, Anne Fischer, Michelle Becker-Hapak, Mark P. Foster, Melissa M. Berrien-Elliott, Alina D. Schmidt, Marcus Watkins, Amanda F. Cashen, Kilannin Krysiak, Kami J. Maddocks, Nina D. Wagner-Johnston, Jingqin Luo, Obi L. Griffith, Zachary L. Skidmore, Todd A. Fehniger, Sweta Desai, Jeffrey P. Ward
Publikováno v:
Blood
New therapies are needed for patients with relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) who do not benefit from or are ineligible for stem cell transplant and chimeric antigen receptor therapy. The CD30-targeted, antibody-drug
Autor:
Lindsey Hendrickson, Iya Znoyko, James Kalmuk, Daynna J. Wolff, Irl Brian Greenwell, Zane Chiad, Cynthia A. Schandl, Sandra Mazzoni, Nina D. Wagner-Johnston, Brian T. Hess
Publikováno v:
Cancer Genetics. :18-22
Richter transformation (RT) refers to the development of an aggressive lymphoma in patients with pre-existing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It carries a poor prognosis secondary to poor response to therapy or rapi
Autor:
Gang Zheng, Philippa Ashmore, Elizabeth S Mayne, Moosa Patel, Tanvier Omar, Sugeshnee Pather, Samantha L. Vogt, Wendy S. Stevens, Neil A. Martinson, Atul Lakha, Richard F. Ambinder, Christopher D. Gocke, Rena R. Xian, Nina D. Wagner-Johnston, Jennifer Stone, Lisa Haley, Vinitha Philip
Publikováno v:
JCO Global Oncology
PURPOSE Diagnosis of AIDS lymphoma in low-resource settings, like South Africa, is often delayed, leaving patients with limited treatment options. In tuberculosis (TB) endemic regions, overlapping signs and symptoms often lead to diagnostic delays. A
Autor:
Ranjan Tiwari, Nina Worel, Michael R. Bishop, Paolo Corradini, Stephan Mielke, Monalisa Ghosh, Joseph P. McGuirk, Lloyd E. Damon, Peter Borchmann, Marcela Martinez-Prieto, Harald Holte, Stephen J. Schuster, Stephen Ronan Foley, Murali Janakiram, Gilles Salles, Isabelle Fleury, Richard T. Maziarz, Takanori Teshima, Koji Kato, Koji Izutsu, Marie José Kersten, Nina D. Wagner-Johnston, Jingmei Hsu, Edmund K. Waller, Jason R. Westin, Constantine S. Tam, P. Joy Ho, Samantha Jaglowski, Xia Han
Publikováno v:
lancet oncology, 22(10), 1403-1415. Lancet Publishing Group
Summary Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response rate was 52% and the complete response rate was 40% in 93 ev
Publikováno v:
Leukemia & Lymphoma. 62:3019-3022
SARS-CoV2 is a novel betacoronavirus that emerged in 2019 and has resulted in a global pandemic of coronavirus disease 2019 (COVID-19) [1]. COVID-19 can cause progressive respiratory failure, which...
Autor:
Michael S. Hughes, Cole H. Sterling, Ravi Varadhan, Richard F. Ambinder, Richard J. Jones, Ronald J. Sweren, Sima Rozati, Javier Bolaños-Meade, Leo Luznik, Philip H. Imus, Syed Abbas Ali, Ivan M. Borrello, Carol Ann Huff, T. Jain, Alexander Ambinder, Amy E. DeZern, Christian B. Gocke, Douglas E. Gladstone, Lode J. Swinnen, Nina D. Wagner-Johnston, Ephraim J. Fuchs
Publikováno v:
Leukemialymphoma. 63(12)
Autor:
Nina D. Wagner-Johnston, Lin Gu, Rebecca J. Chan, Guan Xing, Nishanthan Rajakumaraswamy, Bianca Ruzicka, Shuo Ma
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e432-e448
Idelalisib is a phosphatidylinositol 3-kinase δ inhibitor approved for relapsed/refractory follicular lymphoma, a type of indolent non-Hodgkin lymphoma (iNHL), and chronic lymphocytic leukemia (CLL). Idelalisib-triggered adverse events (AEs) may be
Autor:
Philip H. Imus, Syed Abbas Ali, Richard J. Jones, Javier Bolaños-Meade, Amy E. DeZern, Christian B. Gocke, Douglas E. Gladstone, Nina D. Wagner-Johnston, Leo Luznik, Lode J. Swinnen, Kevin Jerde, Ivan Borrello, Hua Ling Tsai, Carol Ann Huff, Ravi Varadhan, Robert A. Brodsky, Ephraim J. Fuchs, Richard F. Ambinder
Publikováno v:
Biol Blood Marrow Transplant
Transplant-associated thrombotic microangiopathy (taTMA) is a systemic vascular illness associated with significant morbidity and mortality, resulting from a convergence of risk factors after allogeneic blood or marrow transplantation (alloBMT). The
Autor:
Javier Bolaños-Meade, Gary L. Rosner, Richard F. Ambinder, Amy E. DeZern, Phil Imus, Leo Luznik, Lode J. Swinnen, Ivan Borrello, Hany Elmariah, Nina D. Wagner-Johnston, Kenneth R. Cooke, Syed Abbas Ali, Ephraim J. Fuchs, Marianna Zahurak, Carol Ann Huff, Douglas E. Gladstone, Richard J. Jones, Robert A. Brodsky
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:2075-2081
With post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis, nonmyeloablative (NMA) HLA-haploidentical (haplo) and HLA-matched blood or marrow transplantation (BMT) have comparable outcomes. Previous reports have
Autor:
Javier Bolaños-Meade, Mark Levis, Ivana Gojo, Syed Abbas Ali, Jonathan Webster, Richard J. Jones, Amy E. DeZern, Tania Jain, Douglas E. Gladstone, Lukasz P. Gondek, Nina D. Wagner-Johnston, W. Brian Dalton, Carol Ann Huff, B. Douglas Smith, Gabrielle T. Prince, Hua Ling Tsai, Gabriel Ghiaur, Christian B. Gocke, Leo Luznik, Ivan Borrello, Richard F. Ambinder, Philip H. Imus, Keith W. Pratz, Ephraim J. Fuchs, Margaret M. Showel, Lode J. Swinnen
Publikováno v:
Blood Adv
Allogeneic blood or marrow transplantation (alloBMT) is standard of care for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in first complete remission (CR1). The routine pretransplant and posttransplant use of